AAVAA [AH-vah] Therapeutics is
a first-of-its-kind company championing
AAV-based gene therapies for the treatment,
and cure, of skeletal diseases.
OUR COMPANY
Novel Treatment Options for
Skeletal Diseases
You shouldn’t have to settle for less than the quality of life you deserve. AAVAA Therapeutics is the first gene therapy company to target debilitating and life-threatening skeletal diseases.
OUR INNOVATION
AAV-based Gene Therapy
There are no such things as incurable. It’s only a matter of finding a cure. We believe AAV gene therapy will carry us there. Our single-injection AAV gene therapy will deliver life-long curative treatments for such skeletal diseases as osteoarthritis, osteoporotic fractures and rare bone diseases.
OUR COLLABORATORS
World-class Gene Therapy Champions
AAVAA Therapeutics is spearheading translational research & development efforts in AAV gene therapies for skeletal diseases with state-of-the-art medical institutions worldwide.
OUR NEWS
Highlights
GE Healthcare and UMMS boost viral vector manufacturing
The new large-scale viral vector manufacturing facility, to be housed on the UMMS Worcester...
AAVAA Therapeutics hosts AAV gene therapy symposium.
유전자 치료제 권위자 구아핑 가오 메사추세츠 주립대학교 의과대학 교수가 인터뷰하고 있다. / IT조선 "뇌 희귀병으로 인해 아무런 감정을 느끼지도, 사물을 보지도...
AAVAA Therapeutics co-founder is elected president of ASGCT.
In my first message to the ASGCT membership as president of the Society, I want to thank...